Cargando…

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry

INTRODUCTION: The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and compare the effectiveness of ixekizumab between patients who previously failed secukinumab and those who failed other biologics. We hypothes...

Descripción completa

Detalles Bibliográficos
Autores principales: Lockshin, Benjamin, Harrison, Ryan W., McLean, Robert R., Crabtree, Margaux M., Konicek, Bruce W., Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Burge, Russel T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674822/
https://www.ncbi.nlm.nih.gov/pubmed/36331713
http://dx.doi.org/10.1007/s13555-022-00834-7
_version_ 1784833233349771264
author Lockshin, Benjamin
Harrison, Ryan W.
McLean, Robert R.
Crabtree, Margaux M.
Konicek, Bruce W.
Zhu, Baojin
Malatestinic, William N.
Atiya, Bilal
Murage, Mwangi J.
Burge, Russel T.
author_facet Lockshin, Benjamin
Harrison, Ryan W.
McLean, Robert R.
Crabtree, Margaux M.
Konicek, Bruce W.
Zhu, Baojin
Malatestinic, William N.
Atiya, Bilal
Murage, Mwangi J.
Burge, Russel T.
author_sort Lockshin, Benjamin
collection PubMed
description INTRODUCTION: The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and compare the effectiveness of ixekizumab between patients who previously failed secukinumab and those who failed other biologics. We hypothesized that (1) clinical outcomes and patient-reported outcomes would improve following a switch to IXE, and (2) there would be no differences in responses between patients who previously failed secukinumab and those who failed other biologics. METHODS: Participants (n = 419) included adult psoriasis patients enrolled in the CorEvitas Psoriasis Registry through 9/10/20 who switched to ixekizumab after discontinuing another biologic. Patients were classified by the biologic used immediately prior to ixekizumab and reason for discontinuation: prior secukinumab failure; prior secukinumab non-failure; prior other biologic failure; and prior other biologic non-failure. Discontinuations for efficacy reasons were considered failures; all others were considered non-failures. Baseline descriptive statistics were calculated. Multivariable Poisson regression models estimated the likelihood of response of other failure relative to secukinumab failure. RESULTS: Mean age was 51 years; 48% were women. Psoriasis disease characteristics were similar across prior biologic groups. At 6-month follow-up, disease severity improved for all who initiated ixekizumab after discontinuing another biologic. Secukinumab failure patients who switched to ixekizumab achieved BSA ≤ 1 (49%), BSA ≤ 3 (59%), PASI75 (46%), PASI ≤ 3 (64%), and IGA ≤ 1 (40%). Other failure patients achieved BSA ≤ 1 (55%), BSA ≤ 3 (72%), PASI75 (59%), PASI ≤ 3 (74%), and IGA ≤ 1 (54%). In regression modeling, we observed patients in the other biologics failure group had an increased likelihood of achieving response for BSA ≤ 3, PASI75, PASI90, PASI100, and IGA ≤ 1 compared to patients who failed secukinumab. CONCLUSIONS: These findings suggest that patients with psoriasis who switch to ixekizumab after discontinuing another biologic demonstrate improvement in disease severity after six months. Patients who discontinued biologics other than secukinumab may be more likely to respond to ixekiziumab compared to those who switched from secukinumab. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-022-00834-7.
format Online
Article
Text
id pubmed-9674822
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-96748222022-11-20 Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry Lockshin, Benjamin Harrison, Ryan W. McLean, Robert R. Crabtree, Margaux M. Konicek, Bruce W. Zhu, Baojin Malatestinic, William N. Atiya, Bilal Murage, Mwangi J. Burge, Russel T. Dermatol Ther (Heidelb) Original Research INTRODUCTION: The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and compare the effectiveness of ixekizumab between patients who previously failed secukinumab and those who failed other biologics. We hypothesized that (1) clinical outcomes and patient-reported outcomes would improve following a switch to IXE, and (2) there would be no differences in responses between patients who previously failed secukinumab and those who failed other biologics. METHODS: Participants (n = 419) included adult psoriasis patients enrolled in the CorEvitas Psoriasis Registry through 9/10/20 who switched to ixekizumab after discontinuing another biologic. Patients were classified by the biologic used immediately prior to ixekizumab and reason for discontinuation: prior secukinumab failure; prior secukinumab non-failure; prior other biologic failure; and prior other biologic non-failure. Discontinuations for efficacy reasons were considered failures; all others were considered non-failures. Baseline descriptive statistics were calculated. Multivariable Poisson regression models estimated the likelihood of response of other failure relative to secukinumab failure. RESULTS: Mean age was 51 years; 48% were women. Psoriasis disease characteristics were similar across prior biologic groups. At 6-month follow-up, disease severity improved for all who initiated ixekizumab after discontinuing another biologic. Secukinumab failure patients who switched to ixekizumab achieved BSA ≤ 1 (49%), BSA ≤ 3 (59%), PASI75 (46%), PASI ≤ 3 (64%), and IGA ≤ 1 (40%). Other failure patients achieved BSA ≤ 1 (55%), BSA ≤ 3 (72%), PASI75 (59%), PASI ≤ 3 (74%), and IGA ≤ 1 (54%). In regression modeling, we observed patients in the other biologics failure group had an increased likelihood of achieving response for BSA ≤ 3, PASI75, PASI90, PASI100, and IGA ≤ 1 compared to patients who failed secukinumab. CONCLUSIONS: These findings suggest that patients with psoriasis who switch to ixekizumab after discontinuing another biologic demonstrate improvement in disease severity after six months. Patients who discontinued biologics other than secukinumab may be more likely to respond to ixekiziumab compared to those who switched from secukinumab. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-022-00834-7. Springer Healthcare 2022-11-04 /pmc/articles/PMC9674822/ /pubmed/36331713 http://dx.doi.org/10.1007/s13555-022-00834-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Lockshin, Benjamin
Harrison, Ryan W.
McLean, Robert R.
Crabtree, Margaux M.
Konicek, Bruce W.
Zhu, Baojin
Malatestinic, William N.
Atiya, Bilal
Murage, Mwangi J.
Burge, Russel T.
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
title Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
title_full Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
title_fullStr Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
title_full_unstemmed Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
title_short Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
title_sort outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the corevitas psoriasis registry
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674822/
https://www.ncbi.nlm.nih.gov/pubmed/36331713
http://dx.doi.org/10.1007/s13555-022-00834-7
work_keys_str_mv AT lockshinbenjamin outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT harrisonryanw outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT mcleanrobertr outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT crabtreemargauxm outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT konicekbrucew outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT zhubaojin outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT malatestinicwilliamn outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT atiyabilal outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT muragemwangij outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry
AT burgerusselt outcomesinixekizumabpatientsfollowingexposuretosecukinumabandotherbiologicsinthecorevitaspsoriasisregistry